Buning H Perabo L Coutelle O Quadt-Humme S Hallek M Recent developments in adeno-associated virus vector technology J Gene Med 2008 10 717-733 
Wu Z Asokan A Samulski RJ Adeno-associated virus serotypes: vector toolkit for human gene therapy Mol Ther 2006 14 316-327 
Lebherz C Maguire A Tang W Bennett J Wilson JM Novel AAV serotypes for improved ocular gene transfer J Gene Med 2008 10 375-382 
Schmidt M Voutetakis A Afione S Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity J Virol 2008 82 1399-1406 
Blankinship MJ Gregorevic P Chamberlain JS Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors Mol Ther 2006 13 241-249 
Wang L Herzog RW AAV-mediated gene transfer for treatment of hemophilia Curr Gene Ther 2005 5 349-360 
Buch PK Bainbridge JW Ali RR AAV-mediated gene therapy for retinal disorders: from mouse to man Gene Ther 2008 15 849-857 
Moss RB Milla C Colombo J Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial Hum Gene Ther 2007 18 726-732 
Manno CS Pierce GF Arruda VR Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response Nat Med 2006 12 342-347 
McPhee SW Janson CG Li C Immune responses to AAV in a phase I study for Canavan disease J Gene Med 2006 8 577-588 
Mingozzi F High KA Immune responses to AAV in clinical trials Curr Gene Ther 2007 7 316-324 
Erles K Sebokova P Schlehofer JR Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV) J Med Virol 1999 59 406-411 
Halbert CL Miller AD McNamara S Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors Hum Gene Ther 2006 17 440-447 
Mingozzi F Maus MV Hui DJ CD8(+) T-cell responses to adeno-associated virus capsid in humans Nat Med 2007 13 419-422 
Zaiss AK Muruve DA Immune responses to adeno-associated virus vectors Curr Gene Ther 2005 5 323-331 
Wang Z Allen JM Riddell SR Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy Hum Gene Ther 2007 18 18-26 
Yuasa K Yoshimura M Urasawa N Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products Gene Ther 2007 14 1249-1260 
Cao O Dobrzynski E Wang L Induction and role of regulatory CD4+ CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer Blood 2007 110 1132-1140 
Riviere C Danos O Douar AM Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice Gene Ther 2006 13 1300-1308 
Streilein JW Ocular immune privilege: therapeutic opportunities from an experiment of nature Nat Rev Immunol 2003 3 879-889 
Yamagami S Kawashima H Tsuru T Role of Fas&#8211;Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants Transplantation 1997 64 1107-1111 
Jorgensen A Wiencke AK la CM Human retinal pigment epithelial cell-induced apoptosis in activated T cells Invest Ophthalmol Vis Sci 1998 39 1590-1599 
Camelo S Kezic J McMenamin PG Anterior chamber-associated immune deviation: a review of the anatomical evidence for the afferent arm of this unusual experimental model of ocular immune responses Clin Experiment Ophthalmol 2005 33 426-432 
Sonoda KH Sakamoto T Qiao H The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation Immunology 2005 116 390-399 
Schlichtenbrede FC da CL Stephens C Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy J Gene Med 2003 5 757-764 
Kjellstrom S Bush RA Zeng Y Takada Y Sieving PA Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration Invest Ophthalmol Vis Sci 2007 48 3837-3845 
Bainbridge JW Smith AJ Barker SS Effect of gene therapy on visual function in Leber's congenital amaurosis N Engl J Med 2008 358 2231-2239 
Maguire AM Simonelli F Pierce EA Safety and efficacy of gene transfer for Leber's congenital amaurosis N Engl J Med 2008 358 2240-2248 
Pang JJ Chang B Hawes NL Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA) Mol Vis 2005 11 152-162 
Mistry AR De AM Feudner E Ali RR Thrasher AJ High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors Methods Mol Med 2002 69 445-460 
Rogers WO Weaver CT Kraus LA Visualization of antigen-specific T cell activation and cytokine expression in vivo J Immunol 1997 158 649-657 
Leonard WJ Kronke M Peffer NJ Depper JM Greene WC Interleukin 2 receptor gene expression in normal human T lymphocytes Proc Natl Acad Sci USA 1985 82 6281-6285 
Kim HP Imbert J Leonard WJ Both integrated and differential regulation of components of the IL-2/IL-2 receptor system Cytokine Growth Factor Rev 2006 17 349-366 
Sancho D Gomez M Sanchez-Madrid F CD69 is an immunoregulatory molecule induced following activation Trends Immunol 2005 26 136-140 
Testi R D'Ambrosio D De MR Santoni A The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells Immunol Today 1994 15 479-483 
Boulanger A Liu S Yu S Redmond TM Sequence and structure of the mouse gene for RPE65 Mol Vis 2001 7 283-287 
Bennicelli J Wright JF Komaromy A Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer Mol Ther 2008 16 458-465 
Thomas CE Ehrhardt A Kay MA Progress and problems with the use of viral vectors for gene therapy Nat Rev Genet 2003 4 346-358 
Petry H Brooks A Orme A Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice Gene Ther 2008 15 54-60 
Bennett J Immune response following intraocular delivery of recombinant viral vectors Gene Ther 2003 10 977-982 
Chen J Wu Q Yang P Hsu HC Mountz JD Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX Gene Therapy Mol Ther 2006 13 260-269 
McTiernan CF Mathier MA Zhu X Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts Gene Ther 2007 14 1613-1622 
Vandenberghe LH Wang L Somanathan S Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid Nat Med 2006 12 967-971 
Perabo L Goldnau D White K Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism J Virol 2006 80 7265-7269 
Jiang H Couto LB Patarroyo-White S Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy Blood 2006 108 3321-3328 
Wang Z Kuhr CS Allen JM Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression Mol Ther 2007 15 1160-1166 
Swerdlow SH Campo E Harris NL WHO classification of tumours of haematopoietic and lymphoid tissues 2008 Lyon IARC 
Tefferi A Thiele J Orazi A Kvasnicka HM Barbui T Hanson CA Barosi G Verstovsek S Birgegard G Mesa R Reilly JT Gisslinger H Vannucchi AM Cervantes F Finazzi G Hoffman R Gilliland DG Bloomfield CD Vardiman JW Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 2007 110 4 1092-1097 
Thiele J Kvasnicka HM Facchetti F Franco V Walt J Orazi A European consensus on grading bone marrow fibrosis and assessment of cellularity Haematologica 2005 90 1128-1132 
Fend F Horn T Koch I Vela T Orazi A Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm Leuk Res 2008 32 12 1931-1935 
Wardrop D Steensma DP Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol 2009 144 6 809-817 
Ades L Boehrer S Prebet T Beyne-Rauzy O Legros L Ravoet C Dreyfus F Stamatoullas A Chaury MP Delaunay J Laurent G Vey N Burcheri S Mbida RM Hoarau N Gardin C Fenaux P Efficacy and safety of lenalidomide in intermediate-2-or high risk myelodysplastic syndromes (MDS) with 5q deletion: Results of a phase II study Blood 2009 113 17 3947-3952 
Castro GA Arntzen CJ Immunophysiology of the gut: a research frontier for integrative studies of the common mucosal immune system Am J Physiol 1993 265 G599-610 
Jung C Hugot JP Barreau F Peyer's Patches: The Immune Sensors of the Intestine Int J Inflam 2010 2010 823710 
MacDonald T The gut is still the biggest lymphoid organ in the body Mucosal Immunology 2008 1 246-247 
Neutra MR Mantis NJ Kraehenbuhl JP Collaboration of epithelial cells with organized mucosal lymphoid tissues Nat Immunol 2001 2 1004-1009 
Rescigno M Urbano M Valzasina B Francolini M Rotta G Bonasio R Granucci F Kraehenbuhl JP Ricciardi-Castagnoli P Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria Nat Immunol 2001 2 361-367 
Gorfu G Rivera-Nieves J Ley K Role of beta7 integrins in intestinal lymphocyte homing and retention Curr Mol Med 2009 9 836-850 
Cunliffe RN Mahida YR Expression and regulation of antimicrobial peptides in the gastrointestinal tract J Leukoc Biol 2004 75 49-58 
Plaut AG Trefoil peptides in the defense of the gastrointestinal tract N Engl J Med 1997 336 506-507 
Kim YS Ho SB Intestinal goblet cells and mucins in health and disease: recent insights and progress Curr Gastroenterol Rep 2010 12 319-330 
Cerf-Bensussan N Gaboriau-Routhiau V The immune system and the gut microbiota: friends or foes? Nat Rev Immunol 2010 10 735-744 
Macpherson AJ Hunziker L McCoy K Lamarre A IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms Microbes Infect 2001 3 1021-1035 
Suzuki K Maruya M Kawamoto S Sitnik K Kitamura H Agace WW Fagarasan S The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut Immunity 2010 33 71-83 
Spencer J Barone F Dunn-Walters D Generation of Immunoglobulin diversity in human gut-associated lymphoid tissue Semin Immunol 2009 21 139-146 
Macpherson AJ McCoy KD Johansen FE Brandtzaeg P The immune geography of IgA induction and function Mucosal Immunol 2008 1 11-22 
Maizels RM Yazdanbakhsh M Immune regulation by helminth parasites: cellular and molecular mechanisms Nat Rev Immunol 2003 3 733-744 
Cella M Fuchs A Vermi W Facchetti F Otero K Lennerz JK Doherty JM Mills JC Colonna M A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity Nature 2009 457 722-725 
Takayama T Kamada N Chinen H Okamoto S Kitazume MT Chang J Matuzaki Y Suzuki S Sugita A Koganei K Hisamatsu T Kanai T Hibi T Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease Gastroenterology 2010 139 882-892 892 e881-883
Satoh-Takayama N Vosshenrich CA Lesjean-Pottier S Sawa S Lochner M Rattis F Mention JJ Thiam K Cerf-Bensussan N Mandelboim O Eberl G Di Santo JP Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense Immunity 2008 29 958-970 
Shiomi H Masuda A Nishiumi S Nishida M Takagawa T Shiomi Y Kutsumi H Blumberg RS Azuma T Yoshida M Gamma interferon produced by antigen-specific CD4+ T cells regulates the mucosal immune responses to Citrobacter rodentium infection Infect Immun 2010 78 2653-2666 
Jabri B Ebert E Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue Immunol Rev 2007 215 202-214 
Beagley KW Husband AJ Intraepithelial lymphocytes: origins, distribution, and function Crit Rev Immunol 1998 18 237-254 
Sanz Y De Palma G Gut microbiota and probiotics in modulation of epithelium and gut-associated lymphoid tissue function Int Rev Immunol 2009 28 397-413 
Manicassamy S Reizis B Ravindran R Nakaya H Salazar-Gonzalez RM Wang YC Pulendran B Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine Science 2010 329 849-853 
Kawai T Akira S The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 2010 11 373-384 
Hemmi H Takeuchi O Kawai T Kaisho T Sato S Sanjo H Matsumoto M Hoshino K Wagner H Takeda K Akira S A Toll-like receptor recognizes bacterial DNA Nature 2000 408 740-745 
Kang JY Nan X Jin MS Youn SJ Ryu YH Mah S Han SH Lee H Paik SG Lee JO Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer Immunity 2009 31 873-884 
Hugot JP Chamaillard M Zouali H Lesage S Cezard JP Belaiche J Almer S Tysk C O'Morain CA Gassull M Binder V Finkel Y Cortot A Modigliani R Laurent-Puig P Gower-Rousseau C Macry J Colombel JF Sahbatou M Thomas G Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease Nature 2001 411 599-603 
Keshet Y Seger R The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions Methods Mol Biol 2010 661 3-38 
Malladi V Puthenedam M Williams PH Balakrishnan A Enteropathogenic Escherichia coli outer membrane proteins induce iNOS by activation of NF-kappaB and MAP kinases Inflammation 2004 28 345-353 
Shames SR Auweter SD Finlay BB Co-evolution and exploitation of host cell signaling pathways by bacterial pathogens Int J Biochem Cell Biol 2009 41 380-389 
Sasakawa C A new paradigm of bacteria-gut interplay brought through the study of Shigella Proc Jpn Acad Ser B Phys Biol Sci 2010 86 229-243 
Kim M Ashida H Ogawa M Yoshikawa Y Mimuro H Sasakawa C Bacterial interactions with the host epithelium Cell Host Microbe 2010 8 20-35 
Macdonald TT Monteleone G Immunity, inflammation, and allergy in the gut Science 2005 307 1920-1925 
Iwai H Kim M Yoshikawa Y Ashida H Ogawa M Fujita Y Muller D Kirikae T Jackson PK Kotani S Sasakawa C A bacterial effector targets Mad2L2, an APC inhibitor, to modulate host cell cycling Cell 2007 130 611-623 
Kim M Ogawa M Fujita Y Yoshikawa Y Nagai T Koyama T Nagai S Lange A Fassler R Sasakawa C Bacteria hijack integrin-linked kinase to stabilize focal adhesions and block cell detachment Nature 2009 459 578-582 
Tobe T Beatson SA Taniguchi H Abe H Bailey CM Fivian A Younis R Matthews S Marches O Frankel G Hayashi T Pallen MJ An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination Proc Natl Acad Sci USA 2006 103 14941-14946 
Muenzner P Bachmann V Zimmermann W Hentschel J Hauck CR Human-restricted bacterial pathogens block shedding of epithelial cells by stimulating integrin activation Science 2010 329 1197-1201 
Marches O Ledger TN Boury M Ohara M Tu X Goffaux F Mainil J Rosenshine I Sugai M De Rycke J Oswald E Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition Mol Microbiol 2003 50 1553-1567 
Jubelin G Taieb F Duda DM Hsu Y Samba-Louaka A Nobe R Penary M Watrin C Nougayrede JP Schulman BA Stebbins CE Oswald E Pathogenic bacteria target NEDD8-conjugated cullins to hijack host-cell signaling pathways PLoS Pathog 2010 6 
Samba-Louaka A Nougayrede JP Watrin C Jubelin G Oswald E Taieb F Bacterial cyclomodulin Cif blocks the host cell cycle by stabilizing the cyclin-dependent kinase inhibitors p21 and p27 Cell Microbiol 2008 10 2496-2508 
Shames SR Deng W Guttman JA de Hoog CL Li Y Hardwidge PR Sham HP Vallance BA Foster LJ Finlay BB The pathogenic E. coli type III effector EspZ interacts with host CD98 and facilitates host cell prosurvival signalling Cell Microbiol 2010 12 1322-1339 
Hemrajani C Berger CN Robinson KS Marches O Mousnier A Frankel G NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection Proc Natl Acad Sci USA 2010 107 3129-3134 
Baruch K Gur-Arie L Nadler C Koby S Yerushalmi G Ben-Neriah Y Yogev O Shaulian E Guttman C Zarivach R Rosenshine I Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB Embo J 2010 30 221-231 
Deng W Puente JL Gruenheid S Li Y Vallance BA Vazquez A Barba J Ibarra JA O'Donnell P Metalnikov P Ashman K Lee S Goode D Pawson T Finlay BB Dissecting virulence: systematic and functional analyses of a pathogenicity island Proc Natl Acad Sci USA 2004 101 3597-3602 
Kelly M Hart E Mundy R Marches O Wiles S Badea L Luck S Tauschek M Frankel G Robins-Browne RM Hartland EL Essential role of the type III secretion system effector NleB in colonization of mice by Citrobacter rodentium Infect Immun 2006 74 2328-2337 
Marches O Wiles S Dziva F La Ragione RM Schuller S Best A Phillips AD Hartland EL Woodward MJ Stevens MP Frankel G Characterization of two non-locus of enterocyte effacement-encoded type III-translocated effectors, NleC and NleD, in attaching and effacing pathogens Infect Immun 2005 73 8411-8417 
Bhavsar AP Guttman JA Finlay BB Manipulation of host-cell pathways by bacterial pathogens Nature 2007 449 827-834 
Petty NK Bulgin R Crepin VF Cerdeno-Tarraga AM Schroeder GN Quail MA Lennard N Corton C Barron A Clark L Toribio AL Parkhill J Dougan G Frankel G Thomson NR The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli J Bacteriol 2010 192 525-538 
Garmendia J Frankel G Crepin VF Enteropathogenic and enterohemorrhagic Escherichia coli infections: translocation, translocation, translocation Infect Immun 2005 73 2573-2585 
Czerucka D Dahan S Mograbi B Rossi B Rampal P Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection Infect Immun 2001 69 1298-1305 
Ramirez K Huerta R Oswald E Garcia-Tovar C Hernandez JM Navarro-Garcia F Role of EspA and intimin in expression of proinflammatory cytokines from enterocytes and lymphocytes by rabbit enteropathogenic Escherichia coli-infected rabbits Infect Immun 2005 73 103-113 
Ruchaud-Sparagano MH Maresca M Kenny B Enteropathogenic Escherichia coli (EPEC) inactivate innate immune responses prior to compromising epithelial barrier function Cell Microbiol 2007 9 1909-1921 
Sharma R Tesfay S Tomson FL Kanteti RP Viswanathan VK Hecht G Balance of bacterial pro- and anti-inflammatory mediators dictates net effect of enteropathogenic Escherichia coli on intestinal epithelial cells Am J Physiol Gastrointest Liver Physiol 2006 290 G685-694 
Mumy KL McCormick BA The role of neutrophils in the event of intestinal inflammation Curr Opin Pharmacol 2009 9 697-701 
Gao X Wan F Mateo K Callegari E Wang D Deng W Puente J Li F Chaussee MS Finlay BB Lenardo MJ Hardwidge PR Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function PLoS Pathog 2009 5 e1000708 
Wan F Anderson DE Barnitz RA Snow A Bidere N Zheng L Hegde V Lam LT Staudt LM Levens D Deutsch WA Lenardo MJ Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation Cell 2007 131 927-939 
Kim DW Lenzen G Page AL Legrain P Sansonetti PJ Parsot C The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes Proc Natl Acad Sci USA 2005 102 14046-14051 
Royan SV Jones RM Koutsouris A Roxas JL Falzari K Weflen AW Kim A Bellmeyer A Turner JR Neish AS Rhee KJ Viswanathan VK Hecht GA Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-kappaB activation Mol Microbiol 2010 78 1232-1245 
Iguchi A Thomson NR Ogura Y Saunders D Ooka T Henderson IR Harris D Asadulghani M Kurokawa K Dean P Kenny B Quail MA Thurston S Dougan G Hayashi T Parkhill J Frankel G Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348/69 J Bacteriol 2009 191 347-354 
Wickham ME Lupp C Mascarenhas M Vazquez A Coombes BK Brown NF Coburn BA Deng W Puente JL Karmali MA Finlay BB Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection J Infect Dis 2006 194 819-827 
Newton HJ Pearson JS Badea L Kelly M Lucas M Holloway G Wagstaff KM Dunstone MA Sloan J Whisstock JC Kaper JB Robins-Browne RM Jans DA Frankel G Phillips AD Coulson BS Hartland EL The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65 PLoS Pathog 2010 6 e1000898 
Muhlen S Ruchaud-Sparagano MH Kenny B Proteasome-independent Degradation of Canonical NF{kappa}B Complex Components by the NleC Protein of Pathogenic Escherichia coli J Biol Chem 2010 286 5100-5107 
Pearson JS Riedmaier P Marches O Frankel G Hartland EL A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation Mol Microbiol 2010 
Yen H Ooka T Iguchi A Hayashi T Sugimoto N Tobe T NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA PLoS Pathog 2010 6 e1001231 
Zurawski DV Mumy KL Badea L Prentice JA Hartland EL McCormick BA Maurelli AT The NleE/OspZ family of effector proteins is required for polymorphonuclear transepithelial migration, a characteristic shared by enteropathogenic Escherichia coli and Shigella flexneri infections Infect Immun 2008 76 369-379 
Wickham ME Lupp C Vazquez A Mascarenhas M Coburn B Coombes BK Karmali MA Puente JL Deng W Finlay BB Citrobacter rodentium virulence in mice associates with bacterial load and the type III effector NleE Microbes Infect 2007 9 400-407 
Deng W de Hoog CL Yu HB Li Y Croxen MA Thomas NA Puente JL Foster LJ Finlay BB A comprehensive proteomic analysis of the type III secretome of Citrobacter rodentium J Biol Chem 2010 285 6790-6800 
Nadler C Baruch K Kobi S Mills E Haviv G Farago M Alkalay I Bartfeld S Meyer TF Ben-Neriah Y Rosenshine I The type III secretion effector NleE inhibits NF-kappaB activation PLoS Pathog 2010 6 e1000743 
Vossenkamper A Marches O Fairclough PD Warnes G Stagg AJ Lindsay JO Evans PC Luong le A Croft NM Naik S Frankel G MacDonald TT Inhibition of NF-kappaB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE J Immunol 2010 185 4118-4127 
Fitzhenry RJ Reece S Trabulsi LR Heuschkel R Murch S Thomson M Frankel G Phillips AD Tissue tropism of enteropathogenic Escherichia coli strains belonging to the O55 serogroup Infect Immun 2002 70 4362-4368 
Caron E Hall A Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases Science 1998 282 1717-1721 
Celli J Olivier M Finlay BB Enteropathogenic Escherichia coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways EMBO J 2001 20 1245-1258 
Dong N Liu L Shao F A bacterial effector targets host DH-PH domain RhoGEFs and antagonizes macrophage phagocytosis EMBO J 2010 29 1363-1376 
Iizumi Y Sagara H Kabe Y Azuma M Kume K Ogawa M Nagai T Gillespie PG Sasakawa C Handa H The enteropathogenic E. coli effector EspB facilitates microvillus effacing and antiphagocytosis by inhibiting myosin function Cell Host Microbe 2007 2 383-392 
Marches O Covarelli V Dahan S Cougoule C Bhatta P Frankel G Caron E EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis Cell Microbiol 2008 10 1104-1115 
Martinez-Argudo I Sands C Jepson MA Translocation of enteropathogenic Escherichia coli across an in vitro M cell model is regulated by its type III secretion system Cell Microbiol 2007 9 1538-1546 
Quitard S Dean P Maresca M Kenny B The enteropathogenic Escherichia coli EspF effector molecule inhibits PI-3 kinase-mediated uptake independently of mitochondrial targeting Cell Microbiol 2006 8 972-981 
Holmes A Muhlen S Roe AJ Dean P The EspF effector, a bacterial pathogen's Swiss army knife Infect Immun 2010 78 4445-4453 
Weflen AW Alto NM Viswanathan VK Hecht G E. coli secreted protein F promotes EPEC invasion of intestinal epithelial cells via an SNX9-dependent mechanism Cell Microbiol 2010 12 919-929 
Selyunin AS Sutton SE Weigele BA Reddick LE Orchard RC Bresson SM Tomchick DR Alto NM The assembly of a GTPase-kinase signalling complex by a bacterial catalytic scaffold Nature 2011 469 107-111 
Niedergang F Colucci-Guyon E Dubois T Raposo G Chavrier P ADP ribosylation factor 6 is activated and controls membrane delivery during phagocytosis in macrophages J Cell Biol 2003 161 1143-1150 
Maddocks OD Short AJ Donnenberg MS Bader S Harrison DJ Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans PLoS One 2009 4 e5517 
Spehlmann ME Dann SM Hruz P Hanson E McCole DF Eckmann L CXCR2-dependent mucosal neutrophil influx protects against colitis-associated diarrhea caused by an attaching/effacing lesion-forming bacterial pathogen J Immunol 2009 183 3332-3343 
IAAF.org Home of World Athletics http://www.iaaf.org/mm/document/imported/38451.pdf 
Rodriguez NR Di Marco NM Langley S American College of Sports Medicine position stand. Nutrition and athletic performance Med Sci Sports Exerc 2009 41 709-731 
Friedman JE Lemon PW Effect of chronic endurance exercise on retention of dietary protein Int J Sports Med 1989 10 118-123 
Gaine PC Pikosky MA Martin WF Bolster DR Maresh CM Rodriguez NR Level of dietary protein impacts whole body protein turnover in trained males at rest Metabolism 2006 55 501-507 
Meredith CN Zackin MJ Frontera WR Evans WJ Dietary protein requirements and body protein metabolism in endurance-trained men J Appl Physiol 1989 66 2850-2856 
Genton Clinical Nutrition University: Calorie and macronutrient requirements for physical fitness e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism in press
Sawka MN Burke LM Eichner ER Maughan RJ Montain SJ Stachenfeld NS American College of Sports Medicine position stand. Exercise and fluid replacement Med Sci Sports Exerc 2007 39 377-390 
Fudge BW Easton C Kingsmore D Kiplamai FK Onywera VO Westerterp KR Kayser B Noakes TD Pitsiladis YP Elite Kenyan endurance runners are hydrated day-to-day with ad libitum fluid intake Med Sci Sports Exerc 2008 40 1171-1179 
Onywera VO Kiplamai FK Boit MK Pitsiladis YP Food and macronutrient intake of elite kenyan distance runners Int J Sport Nutr Exerc Metab 2004 14 709-719 
Scott RA Fuku N Onywera VO Boit M Wilson RH Tanaka M W HG Pitsiladis YP Mitochondrial haplogroups associated with elite Kenyan athlete status Med Sci Sports Exerc 2009 41 123-128 
Scott RA Pitsiladis YP Genotypes and distance running: clues from Africa Sports Med 2007 37 424-427 
IAAF.org Home of World Athletics http://www.iaaf.org 
Hamilton B East African running dominance: what is behind it? Br J Sports Med 2000 34 391-394 
Scott RA Georgiades E Wilson RH Goodwin WH Wolde B Pitsiladis YP Demographic characteristics of elite Ethiopian endurance runners Med Sci Sports Exerc 2003 35 1727-1732 
Onywera VO Scott RA Boit MK Pitsiladis YP Demographic characteristics of elite Kenyan endurance runners J Sports Sci 2006 24 415-422 
Christensen DL Van Hall G Hambraeus L Food and macronutrient intake of male adolescent Kalenjin runners in Kenya Br J Nutr 2002 88 711-717 
Mukeshi M Thairu K Nutrition and body build: a Kenyan review World Rev Nutr Diet 1993 72 218-226 
Fudge BW Westerterp KR Kiplamai FK Onywera VO Boit MK Kayser B Pitsiladis YP Evidence of negative energy balance using doubly labelled water in elite Kenyan endurance runners prior to competition Br J Nutr 2006 95 59-66 
Marfell-Jones M Olds T Stewart A Carter L International Standards for Anthropometric Assessment International Society for the Advancement of Kinanthropometry ISAK 2006 2 Potchefstroom 
Lissner L Heitmann BL Lindroos AK Measuring intake in free-living human subjects: a question of bias Proc Nutr Soc 1998 57 333-339 
Ainsworth BE Haskell WL Whitt MC Irwin ML Swartz AM Strath SJ O'Brien WL Bassett DR Jr Schmitz KH Emplaincourt PO Compendium of physical activities: an update of activity codes and MET intensities Med Sci Sports Exerc 2000 32 S498-504 
Schofield WN Predicting basal metabolic rate, new standards and review of previous work Hum Nutr Clin Nutr 1985 39 Suppl 1 5-41 
Fjeld CR Brown KH Schoeller DA Validation of the deuterium oxide method for measuring average daily milk intake in infants Am J Clin Nutr 1988 48 671-679 
Holland B Welch AA Unwin ID Buss DH Paul AA Southgate DAT The composition of foods. Fifth revised and extended edition of McCance RA, Widdowson ED 1991 Cambridge, UK 
Ethiopian Health and Nutrition Research Institute Food Composition Table For Use In Ethiopia Part IV 1998 
Westerterp-Plantenga MS Rolland V Wilson SA Westerterp KR Satiety related to 24 h diet-induced thermogenesis during high protein/carbohydrate vs high fat diets measured in a respiration chamber Eur J Clin Nutr 1999 53 495-502 
Ward MP Milledge JS West JB High Altitude Medicine and Physiology 1995 Chapman &amp; Hall Medical, London 
Coyle EF Jeukendrup AE Oseto MC Hodgkinson BJ Zderic TW Low-fat diet alters intramuscular substrates and reduces lipolysis and fat oxidation during exercise Am J Physiol Endocrinol Metab 2001 280 E391-398 
Cerqueira MT Fry MM Connor WE The food and nutrient intakes of the Tarahumara Indians of Mexico Am J Clin Nutr 1979 32 905-915 
Burke LM Gollan RA Read RS Dietary intakes and food use of groups of elite Australian male athletes Int J Sport Nutr 1991 1 378-394 
Grandjean AC Macronutrient intake of US athletes compared with the general population and recommendations made for athletes Am J Clin Nutr 1989 49 1070-1076 
van Erp-Baart AM Saris WH Binkhorst RA Vos JA Elvers JW Nationwide survey on nutritional habits in elite athletes. Part I. Energy, carbohydrate, protein, and fat intake Int J Sports Med 1989 10 Suppl 1 S3-10 
National Research Council Recommended Dietary Allowances 1989 DC Press: National Academy, Washington 249 
Armstrong LE Costill DL Fink WJ Influence of diuretic-induced dehydration on competitive running performance Med Sci Sports Exerc 1985 17 456-461 
Coyle EF Fluid and fuel intake during exercise J Sports Sci 2004 22 39-55 
Ballantyne GH The historical evolution of anatomic concepts of rectal prolapse Semin Colon Rectal Surg 1991 2 170-179 
Moschowitz AV The pathogenesis, anatomy and cure of prolapse of the rectum Surg Gynecol Obstet 1912 15 7-21 
Broden B Snellman B Procidentia of the rectum studied with cineradiography: a contribution to the discussion of causative mechanism Dis Colon Rectum 1968 11 330-347 
Theuerkauf FJ Jr Beahrs OH Hill JR Rectal prolapsed: causation and surgical treatment Ann Surg 1970 171 819-835 
Shorvon PJ McHugh S Diamant NE Somers S Stevenson GW Defecography in normal volunteers: results and implications Gut 1989 30 1737-1749 
Mellgren A Schultz I Johansson C Dolk A Internal rectal intussusception seldom develops into total rectal prolapse Dis Colon Rectum 1997 40 817-820 
Parks AG Swash M Urich H Sphincter denervation in anorectal incontinence and rectal prolapse Gut 1977 18 656-665 
Kuijpers HC Treatment of complete rectal prolapse: to narrow, to wrap, to suspend, to fix, to encircle, to plicate or to resect? World J Surg 1992 16 826-830 
Altman D Zetterstrom J Schultz I Nordenstam J Hjern F Lopez A Pelvic organ prolapse and urinary incontinence in women with surgically managed rectal prolapse: a population-based case-control study Dis Colon Rectum 2006 49 28-35 
Hamalainen KJ Raivio P Antila S Palmu A Mecklin JP Biofeedback therapy in rectal prolapse patients Dis Colon Rectum 1996 39 262-265 
Corman ML Colon and rectal surgery 2005 Philadelphia Lippincott Williams &amp; Wilkins 
Thiersch C Carl Thiersch 1822-1895. Concerning prolapse of the rectum with special emphasis on the operation by Thiersch Dis Colon Rectum 1988 31 154-155 
Labow S Rubin RJ Hoexter B Salvati EP Perineal repair of rectal procidentia with an elastic fabric sling Dis Colon Rectum 1980 23 467-469 
Poole GV Jr Pennell TC Myers RT Hightower F Modified Thiersch operation for rectal prolapse. Technique and results Am Surg 1985 51 226-229 
Earnshaw JJ Hopkinson BR Late results of silicone rubber perianal suture for rectal prolapse Dis Colon Rectum 1987 30 86-88 
Hunt TM Fraser IA Maybury NK Treatment of rectal prolapse by sphincteric support using silastic rods Br J Surg 1985 72 491-492 
Classic articles in colonic and rectal surgery. Edmond Delorme 1847-1929. On the treatment of total prolapse of the rectum by excision of the rectal mucous membranes or recto-colic Dis Colon Rectum 1985 28 544-553 
Senapati A Nicholls RJ Thomson JP Phillips RK Results of Delorme's procedure for rectal prolapse Dis Colon Rectum 1994 37 456-460 
Watts AM Thompson MR Evaluation of Delorme's procedure as a treatment for full-thickness rectal prolapse Br J Surg 2000 87 218-222 
Lechaux JP Lechaux D Perez M Results of Delorme's procedure for rectal prolapsed: advantages of a modified technique Dis Colon Rectum 1995 38 301-307 
Oliver GC Vachon D Eisenstat TE Rubin RJ Salvati EP Delorme's procedure for complete rectal prolapse in severely debilitated patients: an analysis of 41 cases Dis Colon Rectum 1994 37 461-467 
Byun SW Kim HS Results of Delorme's procedure for rectal prolapse J Korean Soc Coloproctol 2000 16 407-414 
Tobin SA Scott IH Delorme operation for rectal prolapse Br J Surg 1994 81 1681-1684 
Altemeier WA Culbertson WR Schowengerdt C Hunt J Nineteen years' experience with the one-stage perineal repair of rectal prolapse Ann Surg 1971 173 993-1006 
Agachan F Pfeifer J Joo JS Nogueras JJ Weiss EG Wexner SD Results of perineal procedures for the treatment of rectal prolapse Am Surg 1997 63 9-12 
Watts JD Rothenberger DA Buls JG Goldberg SM Nivatvongs S The management of procidentia. 30 years' experience Dis Colon Rectum 1985 28 96-102 
Williams JG Rothenberger DA Madoff RD Goldberg SM Treatment of rectal prolapse in the elderly by perineal rectosigmoidectomy Dis Colon Rectum 1992 35 830-834 
Prasad ML Pearl RK Abcarian H Orsay CP Nelson RL Perineal proctectomy, posterior rectopexy, and postanal levator repair for the treatment of rectal prolapse Dis Colon Rectum 1986 29 547-552 
Rhyu PG Baek MJ Lee MS Kim CH Song OP Cho MS Treatment of rectal prolapse by a perineal rectosigmoidectomy J Korean Surg Soc 1998 55 868-873 
Pikarsky AJ Joo JS Wexner SD Weiss EG Nogueras JJ Agachan F Recurrent rectal prolapse: what is the next good option? Dis Colon Rectum 2000 43 1273-1276 
Fengler SA Pearl RK Prasad ML Orsay CP Cintron JR Hambrick E Management of recurrent rectal prolapse Dis Colon Rectum 1997 40 832-834 
Yamana T Iwadare J Mucosal plication (Gant-Miwa procedure) with anal encircling for rectal prolapsed: a review of the Japanese experience Dis Colon Rectum 2003 46 S94-S99 
Lim SW Lee CH Lee KR Yoo CJ Park SY Kim HS Clinical analysis of Gant-Miwa operation with Thiersch wiring based on 50 cases of rectal prolapse J Korean Soc Coloproctol 1996 12 503-510 
Kim JD Ye BK Jo HJ Oh NG Transanal posterior anorectoplasty of rectal prolapse J Korean Soc Coloproctol 2002 18 269-273 
Muir EG The surgical treatment of severe rectal prolapse Proc R Soc Med 1959 52 Suppl 104-105 
Novell JR Osborne MJ Winslet MC Lewis AA Prospective randomized trial of Ivalon sponge versus sutured rectopexy for full-thickness rectal prolapse Br J Surg 1994 81 904-906 
Kim KY Shin JH Kim YS A clinical analysis of rectal prolapse treated by presacral rectopexy J Korean Soc Coloproctol 1991 7 45-49 
Briel JW Schouten WR Boerma MO Long-term results of suture rectopexy in patients with fecal incontinence associated with incomplete rectal prolapse Dis Colon Rectum 1997 40 1228-1232 
Holmstrom B Broden G Dolk A Results of the Ripstein operation in the treatment of rectal prolapse and internal rectal procidentia Dis Colon Rectum 1986 29 845-848 
Tjandra JJ Fazio VW Church JM Milsom JW Oakley JR Lavery IC Ripstein procedure is an effective treatment for rectal prolapse without constipation Dis Colon Rectum 1993 36 501-507 
Roberts PL Schoetz DJ Jr Coller JA Veidenheimer MC Ripstein procedure. Lahey Clinic experience: 1963-1985 Arch Surg 1988 123 554-557 
Launer DP Fazio VW Weakley FL Turnhull RB Jr Jagelman DG Lavery IC The Ripstein procedure: a 16-year experience Dis Colon Rectum 1982 25 41-45 
Schultz I Mellgren A Dolk A Johansson C Holmstr&#246;m B Long-term results and functional outcome after Ripstein rectopexy Dis Colon Rectum 2000 43 35-43 
Winde G Reers B Nottberg H Berns T Meyer J B&#252;nte H Clinical and functional results of abdominal rectopexy with absorbable mesh-graft for treatment of complete rectal prolapse Eur J Surg 1993 159 301-305 
McMahan JD Ripstein CB Rectal prolapsed: an update on the rectal sling procedure Am Surg 1987 53 37-40 
Wells C New operation for rectal prolapse Proc R Soc Med 1959 52 602-603 
Penfold JC Hawley PR Experiences of Ivalon-sponge implant for complete rectal prolapse at St. Mark's Hospital, 1960-70 Br J Surg 1972 59 846-848 
Morgan CN Porter NH Klugman DJ Ivalon (polyvinyl alcohol) sponge in the repair of complete rectal prolapse Br J Surg 1972 59 841-846 
Keighley MR Fielding JW Alexander-Williams J Results of Marlex mesh abdominal rectopexy for rectal prolapse in 100 consecutive patients Br J Surg 1983 70 229-232 
Yakut M Kaymakcioglu N Simsek A Tan A Sen D Surgical treatment of rectal prolapsed: a retrospective analysis of 94 cases Int Surg 1998 83 53-55 
Aitola PT Hiltunen KM Matikainen MJ Functional results of operative treatment of rectal prolapse over an 11-year period: emphasis on transabdominal approach Dis Colon Rectum 1999 42 655-660 
Ross AH Thomson JP Management of infection after prosthetic abdominal rectopexy (Wells' procedure) Br J Surg 1989 76 610-612 
Kim DS Tsang CB Wong WD Lowry AC Goldberg SM Madoff RD Complete rectal prolapse: evolution of management and results Dis Colon Rectum 1999 42 460-466 
Cirocco WC Brown AC Anterior resection for the treatment of rectal prolapse: a 20-year experience Am Surg 1993 59 265-269 
Luukkonen P Mikkonen U Jarvinen H Abdominal rectopexy with sigmoidectomy vs. rectopexy alone for rectal prolapse: a prospective, randomized study Int J Colorectal Dis 1992 7 219-222 
Frykman HM Goldberg SM The surgical treatment of rectal procidentia Surg Gynecol Obstet 1969 129 1225-1230 
Mollen RM Kuijpers JH van Hoek F Effects of rectal mobilization and lateral ligaments division on colonic and anorectal function Dis Colon Rectum 2000 43 1283-1287 
Speakman CT Madden MV Nicholls RJ Kamm MA Lateral ligament division during rectopexy causes constipation but prevents recurrence: results of a prospective randomized study Br J Surg 1991 78 1431-1433 
Bachoo P Brazzelli M Grant A Surgery for complete rectal prolapse in adults Cochrane Database Syst Rev 2000 2 CD001758 
Kellokumpu IH Vironen J Scheinin T Laparoscopic repair of rectal prolapse: a prospective study evaluating surgical outcome and changes in symptoms and bowel function Surg Endosc 2000 14 634-640 
Kessler H Jerby BL Milsom JW Successful treatment of rectal prolapse by laparoscopic suture rectopexy Surg Endosc 1999 13 858-861 
Bruch HP Herold A Schiedeck T Schwandner O Laparoscopic surgery for rectal prolapse and outlet obstruction Dis Colon Rectum 1999 42 1189-1194 
Benoist S Taffinder N Gould S Chang A Darzi A Functional results two years after laparoscopic rectopexy Am J Surg 2001 182 168-173 
Scaglia M Fasth S Hallgren T Nordgren S Oresland T Hulten L Abdominal rectopexy for rectal prolapse. Influence of surgical technique on functional outcome Dis Colon Rectum 1994 37 805-813 
Himpens J Cadiere GB Bruyns J Vertruyen M Laparoscopic rectopexy according to Wells Surg Endosc 1999 13 139-141 
Boccasanta P Venturi M Reitano MC Salamina G Rosati R Montorsi M Laparotomic vs. laparoscopic rectopexy in complete rectal prolapse Dig Surg 1999 16 415-419 
Zittel TT Manncke K Haug S Schafer JF Kreis ME Becker HD Functional results after laparoscopic rectopexy for rectal prolapse J Gastrointest Surg 2000 4 632-641 
Dulucq JL Wintringer P Mahajna A Clinical and functional outcome of laparoscopic posterior rectopexy (Wells) for full-thickness rectal prolapsed: a prospective study Surg Endosc 2007 21 2226-2230 
Purkayastha S Tekkis P Athanasiou T Aziz O Paraskevas P Ziprin P A comparison of open vs. laparoscopic abdominal rectopexy for full-thickness rectal prolapse: a meta-analysis Dis Colon Rectum 2005 48 1930-1940 
Solomon MJ Young CJ Eyers AA Roberts RA Randomized clinical trial of laparoscopic versus open abdominal rectopexy for rectal prolapse Br J Surg 2002 89 35-39 
Ashari LH Lumley JW Stevenson AR Stitz RW Laparoscopically-assisted resection rectopexy for rectal prolapse: ten years' experience Dis Colon Rectum 2005 48 982-987 
Xynos E Chrysos E Tsiaoussis J Epanomeritakis E Vassilakis JS Resection rectopexy for rectal prolapse. The laparoscopic approach Surg Endosc 1999 13 862-864 
Yoon SG Kim KU Noh KY Lee JK Kim KY Laparoscopic suture rectopexy for rectal prolapse J Korean Soc Coloproctol 2002 18 89-94 
Jacobs LK Lin YJ Orkin BA The best operation for rectal prolapse Surg Clin North Am 1997 77 49-70 
Madiba TE Baig MK Wexner SD Surgical management of rectal prolapse Arch Surg 2005 140 63-73 
Schiedeck TH Schwandner O Scheele J Farke S Bruch HP Rectal prolapse: which surgical option is appropriate? Langenbecks Arch Surg 2005 390 8-14 
Gourgiotis S Baratsis S Rectal prolapse Int J Colorectal Dis 2007 22 231-243 
Adachi J Hasegawa M Model of amino acid substitution in proteins encoded by mitochondrial DNA J Mol Evol 1996 42 459-468 
Clackson T Wells JA A hot spot of binding energy in a hormone-receptor interface Science 1995 267 383-386 
Frank SA Immunology and evolution of infectious disease 2002 Princeton, NJ Princeton University Press 
Goldman N Whelan S A novel use of equilibrium frequencies in models of sequence evolution Mol Biol Evol 2002 19 1821-1831 
Gupta V Earl DJ Deem MW Quantifying influenza vaccine efficacy and antigenic distance Vaccine 2006 24 3881-3888 
Henikoff S Henikoff JG Amino-acid substitution matrices from protein blocks Proc Natl Acad Sci USA 1992 89 10915-10919 
Kaverin NV Matrosovich MN Gambaryan AS Rudneva IA Shilov AA Varich NL Makarova NV Kropotkina EA Sinitsin BV Intergenic HA&#8211;NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes Virus Res 2000 66 123-129 
Kosiol C Goldman N Different versions of the Dayhoff rate matrix Mol Biol Evol 2005 22 193-199 
Leunissen JA Hooven HW Jong WW Extreme differences in charge changes during protein evolution J Mol Evol 1990 31 33-39 
Lowen AC Mubareka S Tumpey TM Garc&#237;a-Sastre A Palese P The Guinea pig as a transmission model for human influenza viruses Proc Natl Acad Sci USA 2006 103 9988-9992 
http://www.flu.lanl.gov/ 
McDonald JH Apparent trends of amino acid gain and loss in protein evolution due to nearly neutral variation Mol Biol Evol 2006 23 240-244 
Minin VN Suchard MA Counting labeled transitions in continuous-time markov models of evolution J Math Biol 2008 56 391-412 
Mu&#241;oz ET Deem MW Epitope analysis for influenza vaccine design Vaccine 2005 23 1144-1148 
M&#252;ller T Vingron M Modeling amino acid replacement J Comput Biol 2000 7 761-776 
M&#252;ller T Spang R Vingron M Estimating amino acid substitution models: a comparison of Dayhoff&#8217;s estimator, the resolvent approach and a maximum likelihood method Mol Biol Evol 2002 19 8-13 
Nakajima S Nakajima K Nobusawa E Zhao J Tanaka S Fukuzawa K Comparison of epitope structures of H3HAs through protein modeling of influenza a virus hemagglutinin: mechanism for selection of antigenic variants in the presence of a monoclonal antibody Microbiol Immunol 2007 51 1179-1187 
Pan K Deem MW Comment on Ndifon et&#160;al., &#8220;On the use of hemagglutination-inhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness&#8221; Vaccine 2009 27 5033-5034 
Sinha N Mohan S Lipschultz CA Smith-Gill SJ Differences in electrostatic properties at antibody-antigen binding sites: Implications for specificity and cross-reactivity Biophys J 2002 83 2946-2968 
Smith DJ Forrest S Ackley DH Perelson AS Variable efficacy of repeated annual influenza vaccination Proc Natl Acad Sci USA 1999 96 14001-14006 
Smith DJ Lapedes AS Jong JC Bestebroer TM Rimmelzwaan GF Osterhaus ADME Fouchier RAM Mapping the antigenic and genetic evolution of influenza virus Science 2004 305 371-376 
Sun J Deem MW Zaman MH Statistical mechanics of the immune response to vaccines Statistical mechanics of cellular systems and processes 2009 Cambridge Cambridge University Press 177-213 
Sun J Earl DJ Deem MW Localization and glassy dynamics in the immune system Mod Phys Lett B 2006 20 63-95 
Thorne JL Models of protein sequence evolution and their applications Curr Opin Genet Dev 2000 10 602-605 
Tseng YY Liang J Estimation of amino acid residue substitution rates at local spatial regions and application in protein function inference: a Bayesian Monte Carlo approach Mol Biol Evol 2006 23 421-436 
Bechstedt S Albert JT Kreil DP M&#252;ller-Reichert T G&#246;pfert MC Howard J A doublecortin-domain-containing microtubule-associated protein (DCX-EMAP) required for mechanoreception in Drosophila sensory cilia Nat Commun 2010 1 1-11 
Bounoutas A O'Hagan R Chalfie M The multipurpose 15-protofilament microtubules in C. elegans have specific roles in mechanosensation Curr Biol 2009 19 1362-1367 
Chalfie M Neurosensory mechanotransduction Nat Rev Mol Cell Biol 2009 10 44-52 
Chalfie M Au M Genetic control of differentiation of the Caenorhabditis elegans touch receptor neurons Science 1989 243 1027-1033 
Chelur DS Ernstrom GG Goodman MB Yao CA Chen L O'Hagan R Chalfie M The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel Nature 2002 420 669-673 
Cheng LE Song W Looger LL Jan LY Jan YN The role of the TRP channel NompC in Drosophila larval and adult locomotion Neuron 2010 67 373-380 
Cueva JG Mulholland A Goodman MB Nanoscale organization of the MEC-4 DEG/ENaC sensory mechanotransduction channel in Caenorhabditis elegans touch receptor neurons J Neurosci 2007 27 14089-14098 
Eberl DF Hardy RW Kernan MJ Genetically similar transduction mechanisms for touch and hearing in Drosophila J Neurosci 2000 20 5981-5988 
Emtage L Gu G Hartwieg E Chalfie M Extracellular proteins organize the mechanosensory channel complex in C. elegans touch receptor neurons Neuron 2004 44 795-807 
Gillespie PG Walker RG Molecular basis of mechanosensory transduction Nature 2001 413 194-202 
Gong Z Son W Chung YD Kim J Shin DW McClung CA Lee Y Lee HW Chang DJ Kaang BK Cho H Oh U Hirsh J Kernan MJ Kim C Two interdependent channel subunits, inactive and Nanchung, mediate hearing in Drosophila J Neurosci 2004 24 9059-9066 
Goodman MB Ernstrom GG Chelur DS O'Hagan R Yao CA Chalfie M MEC-2 regulates C. elegans DEG/ENaC channels needed for mechanosensation Nature 2002 415 1039-1042 
Gopfert MC Albert JT Nadrowski B Kamikouchi A Specification of auditory sensitivity by Drosophila TRP channels Nat Neurosci 2006 9 999-1000 
Howard J Bechstedt S Hypothesis: a helix of ankyrin repeats of the NOMPC-TRP ion channel is the gating spring of mechanoreceptors Curr Biol 2004 14 R224-R226 
Hudspeth AJ How the ear's works work Nature 1989 341 397-404 
Kamikouchi A Inagaki HK Effertz T Hendrich O Fiala A Gopfert MC Ito K The neural basis of Drosophila gravity-sensing and hearing Nature 2009 458 165-171 
Kang L Gao J Schafer WR Xie Z Xu XZ C. elegans TRP family protein TRP-4 is a pore-forming subunit of a native mechanotransduction channel Neuron 2010 67 381-391 
Kazmierczak P Sakaguchi H Tokita J Wilson-Kubalek EM Milligan RA Muller U Kachar B Cadherin 23 and protocadherin 15 interact to form tip-link filaments in sensory hair cells Nature 2007 449 87-91 
Keil TA Functional morphology of insect mechanoreceptors Microsc Res Tech 1997 39 506-531 
Kernan MJ Mechanotransduction and auditory transduction in Drosophila Pflugers Arch 2007 454 703-720 
Kernan M Cowan D Zuker C Genetic dissection of mechanosensory transduction: mechanoreception-defective mutations of Drosophila Neuron 1994 12 1195-1206 
Kim J Chung YD Park DY Choi S Shin DW Soh H Lee HW Son W Yim J Park CS Kernan MJ Kim C A TRPV family ion channel required for hearing in Drosophila Nature 2003 424 81-84 
Lee J Moon S Cha Y Chung YD Drosophila TRPN(=NOMPC) channel localizes to the distal end of mechanosensory cilia PLoS One 2010 5 e11012 
Li W Feng Z Sternberg PW Xu XZ A C. elegans stretch receptor neuron revealed by a mechanosensitive TRP channel homologue Nature 2006 440 684-687 
O'Hagan R Chalfie M Goodman MB The MEC-4 DEG/ENaC channel of Caenorhabditis elegans touch receptor neurons transduces mechanical signals Nat Neurosci 2005 8 43-50 
Pickles JO Comis SD Osborne MP Cross-links between stereocilia in the guinea pig organ of Corti, and their possible relation to sensory transduction Hear Res 1984 15 103-112 
Richard M Grawe F Knust E DPATJ plays a role in retinal morphogenesis and protects against light-dependent degeneration of photoreceptor cells in the Drosophila eye Dev Dyn 2006 235 895-907 
Shin JB Adams D Paukert M Siba M Sidi S Levin M Gillespie PG Grunder S Xenopus TRPN1 (NOMPC) localizes to microtubule-based cilia in epithelial cells, including inner-ear hair cells Proc Natl Acad Sci USA 2005 102 12572-12577 
Sidi S Friedrich RW Nicolson T NompC TRP channel required for vertebrate sensory hair cell mechanotransduction Science 2003 301 96-99 
Walker RG Willingham AT Zuker CS A Drosophila mechanosensory transduction channel Science 2000 287 2229-2234 
Yorozu S Wong A Fischer BJ Dankert H Kernan MJ Kamikouchi A Ito K Anderson DJ Distinct sensory representations of wind and near-field sound in the Drosophila brain Nature 2009 458 201-205 
Abzhanov A Kaufman TC Homeotic genes and the arthropod head: expression patterns of the labial, proboscipedia, and Deformed genes in crustaceans and insects Proc Natl Acad Sci USA 1999 96 10224-10229 
Bejerano G Siepel AC Kent WJ Haussler D Computational screening of conserved genomic DNA in search of functional noncoding elements Nat Meth 2005 2 535-545 
Bischof J Maeda RK Hediger M Karch F Basler K An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases Proc Natl Acad Sci USA 2007 104 3312-3317 
Bucher G Wimmer EA Beetle a-head. B.I.F Futura 2005 20 164-169 
Butler JE Kadonaga JT Enhancer&#8211;promoter specificity mediated by DPE or TATA core promoter motifs Genes Dev 2001 15 2515-2519 
Campos-Ortega JA Hartenstein V The embryonic development of Drosophila melenogaster 1997 2 Berlin Springer 
Cartharius K Frech K Grote K Klocke B Haltmeier M Klingenhoff A Frisch M Bayerlein M Werner T MatInspector and beyond: promoter analysis based on transcription factor binding sites Bioinformatics 2005 21 2933-2942 
Cerny AC Grossmann D Bucher G Klingler M The Tribolium ortholog of knirps and knirps-related is crucial for head segmentation but plays a minor role during abdominal patterning Dev Biol 2008 321 284-294 
Chang T Mazotta J Dumstrei K Dumitrescu A Hartenstein V Dpp and Hh signaling in the Drosophila embryonic eye field Development 2001 128 4691-4704 
Chipman AD Akam M The segmentation cascade in the centipede Strigamia maritima: involvement of the Notch pathway and pair-rule gene homologues Dev Biol 2008 319 160-169 
Choe CP Brown SJ Evolutionary flexibility of pair-rule patterning revealed by functional analysis of secondary pair-rule genes, paired and sloppy-paired in the short-germ insect, Tribolium castaneum Dev Biol 2007 302 281-294 
Choe CP Brown SJ Genetic regulation of engrailed and wingless in Tribolium segmentation and the evolution of pair-rule segmentation Dev Biol 2009 325 482-491 
Choe CP Miller SC Brown SJ A pair-rule gene circuit defines segments sequentially in the short-germ insect Tribolium castaneum Proc Natl Acad Sci USA 2006 103 6560-6564 
Churchill ME Jones DN Glaser T Hefner H Searles MA Travers AA HMG-D is an architecture-specific protein that preferentially binds to DNA containing the dinucleotide TG EMBO J 1995 14 1264-1275 
Cohen SM J&#252;rgens G Mediation of Drosophila head development by gap-like segmentation genes Nature 1990 346 482-485 
Cohen S J&#252;rgens G Drosophila headlines Trends Genet 1991 7 267-272 
Cr&#233;mazy F Berta P Girard F Genome-wide analysis of Sox genes in Drosophila melanogaster Mech Dev 2001 109 371-375 
Crozatier M Valle D Dubois L Ibnsouda S Vincent A Collier, a novel regulator of Drosophila head development, is expressed in a single mitotic domain Curr Biol 1996 6 707-718 
Crozatier M Valle D Dubois L Ibnsouda S Vincent A Head versus trunk patterning in the Drosophila embryo; collier requirement for formation of the intercalary segment Development 1999 126 4385-4394 
Dailey L Basilico C Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes J Cell Physiol 2001 186 315-328 
Damen WG Parasegmental organization of the spider embryo implies that the parasegment is an evolutionary conserved entity in arthropod embryogenesis Development 2002 129 1239-1250 
Velasco B Mandal L Mkrtchyan M Hartenstein V Subdivision and developmental fate of the head mesoderm in Drosophila melanogaster Dev Genes Evol 2006 216 39-51 
Dragan AI Read CM Makeyeva EN Milgotina EI Churchill ME Crane-Robinson C Privalov PL DNA binding and bending by HMG boxes: energetic determinants of specificity J Mol Biol 2004 343 371-393 
Dray N Tessmar-Raible K Gouar M Vibert L Christodoulou F Schipany K Guillou A Zantke J Snyman H B&#233;hague J Vervoort M Arendt D Balavoine G Hedgehog signaling regulates segment formation in the annelid Platynereis Science 2010 329 339-342 
Gallitano-Mendel A Finkelstein R Novel segment polarity gene interactions during embryonic head development in Drosophila Dev Biol 1997 192 599-613 
Giese K Pagel J Grosschedl R Functional analysis of DNA bending and unwinding by the high mobility group domain of LEF-1 Proc Natl Acad Sci USA 1997 94 12845-12850 
Grossniklaus U Cadigan KM Gehring WJ Three maternal coordinate systems cooperate in the patterning of the Drosophila head Development 1994 120 3155-3171 
Horn C Wimmer EA A versatile vector set for animal transgenesis Dev Genes Evol 2000 210 630-637 
Horn C Jaunich B Wimmer EA Highly sensitive, fluorescent transformation marker for Drosophila transgenesis Dev Genes Evol 2000 210 623-629 
Hsu JY Juven-Gershon T Marr MT 2nd Wright KJ Tjian R Kadonaga JT TBP, Mot1, and NC2 establish a regulatory circuit that controls DPE-dependent versus TATA-dependent transcription Genes Dev 2008 22 2353-2358 
Juven-Gershon T Kadonaga JT Regulation of gene expression via the core promoter and the basal transcriptional machinery Dev Biol 2010 339 225-229 
Juven-Gershon T Hsu JY Kadonaga JT Caudal, a key developmental regulator, is a DPE-specific transcriptional factor Genes Dev 2008 22 2823-2830 
Kamachi Y Uchikawa M Collignon J Lovell-Badge R Kondoh H Involvement of Sox1, 2 and 3 in the early and subsequent molecular events of lens induction Development 1998 125 2521-2532 
Kamachi Y Uchikawa M Tanouchi A Sekido R Kondoh H Pax6 and SOX2 form a co-DNA-binding partner complex that regulates initiation of lens development Genes Dev 2001 15 1272-1286 
Kondoh H Kamachi Y SOX-partner code for cell specification: regulatory target selection and underlying molecular mechanisms Int J Biochem Cell Biol 2010 42 391-399 
Kutach AK Kadonaga JT The downstream promoter element DPE appears to be as widely used as the TATA box in Drosophila core promoters Mol Cell Biol 2000 20 4754-4764 
Lee HH Frasch M Wingless effects mesoderm patterning and ectoderm segmentation events via induction of its downstream target sloppy paired Development 2000 127 5497-5508 
Lee JJ Kessler DP Parks S Beachy PA Secretion and localized transcription suggest a role in positional signaling for products of the segmentation gene hedgehog Cell 1992 71 33-50 
Lefebvre V Dumitriu B Penzo-M&#233;ndez A Han Y Pallavi B Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors Int J Biochem Cell Biol 2007 39 2195-2214 
Lessing D Nusse R Expression of wingless in the Drosophila embryo: a conserved cis-acting element lacking conserved Ci-binding sites is required for patched-mediated repression Development 1998 125 1469-1476 
Lim CY Santoso B Boulay T Dong E Ohler U Kadonaga JT The MTE, a new core promoter element for transcription by RNA polymerase II Genes Dev 2004 18 1606-1617 
Liu Z Yang X Dong Y Friedrich M Tracking down the &#8220;head blob&#8221;: comparative analysis of wingless expression in the developing insect procephalon reveals progressive reduction of embryonic visual system patterning in higher insects Arthropod Struct Dev 2006 35 341-356 
Love JJ Li X Case DA Giese K Grosschedl R Wright PE Structural basis for DNA bending by the architectural transcription factor LEF-1 Nature 1995 376 791-795 
Maderspacher F Bucher G Klingler M Pair-rule and gap gene mutants in the flour beetle Tribolium castaneum Dev Genes Evol 1998 208 558-568 
McGinnis W Krumlauf R Homeobox genes and axial patterning Cell 1992 68 283-302 
McKimmie C Woerfel G Russell S Conserved genomic organisation of group B Sox genes in insects BMC Genet 2005 6 26 
Minelli A A three-phase model of arthropod segmentation Dev Genes Evol 2001 211 509-521 
Mohler J Spatial regulation of segment polarity gene expression in the anterior terminal region of the Drosophila blastoderm embryo Mech Dev 1995 50 151-161 
Mohler J Mahaffey JW Deutsch E Vani K Control of Drosophila head segment identity by the bZIP homeotic gene cnc Development 1995 121 237-247 
Nambu PA Nambu JR The Drosophila fish-hook gene encodes a HMG domain protein essential for segmentation and CNS development Development 1996 122 3467-3475 
Onichtchouk D Geier F Polok B Messerschmidt DM M&#246;ssner R Wendik B Song S Taylor V Timmer J Driever W Zebrafish Pou5f1-dependent transcriptional networks in temporal control of early development Mol Syst Biol 2010 6 354 
Patel NH Developmental evolution: insights from studies of insect segmentation Science 1994 266 581-590 
Pechmann M McGregor AP Schwager EE Feitosa NM Damen WG Dynamic gene expression is required for anterior regionalization in a spider Proc Natl Acad Sci USA 2009 106 1468-1472 
Posnien N Bucher G Formation of the insect head involves lateral contribution of the intercalary segment, which depends on Tc-labial function Dev Biol 2010 338 107-116 
Rehm EJ Hannibal RL Chaw RC Vargas-Vila MA Patel NH In situ hybridization of labeled RNA probes to fixed Parhyale hawaiensis embryos Cold Spring Harb Protoc 2009 
Reichert H Simeone A Conserved usage of gap and homeotic genes in patterning the CNS Curr Opin Neurobiol 1999 9 589-595 
Remane A Enstehung der Metamerie der Wirbellosen Zool Anz Suppl 1950 14 16-23 
Rogers BT Kaufman TC Structure of the insect head in ontogeny and phylogeny: a view from Drosophila Int Rev Cytol 1997 174 1-84 
Russell SR Sanchez-Soriano N Wright CR Ashburner M The Dichaete gene of Drosophila melanogaster encodes a SOX-domain protein required for embryonic segmentation Development 1996 122 3669-3676 
S&#225;nchez-Soriano N Russell S Regulatory mutations of the Drosophila Sox gene Dichaete reveal new functions in embryonic brain and hindgut development Dev Biol 2000 220 307-321 
Sander K Goodwin BC , Holder N , Wylie CC The evolution of patterning mechanisms: gleanings from insect embryogenesis and spermatogenesis Development and evolution 1983 Cambridge Cambridge University Press 137-160 
Schaeper ND Pechmann M Damen WG Prpic NM Wimmer EA Evolutionary plasticity of collier function in head development of diverse arthropods Dev Biol 2010 344 363-376 
Schinko JB Kreuzer N Offen N Posnien N Wimmer EA Bucher G Divergent functions of orthodenticle, empty spiracles and buttonhead in early head patterning of the beetle Tribolium castaneum (Coleoptera) Dev Biol 2008 317 600-613 
Schmidt-Ott U Technau GM Expression of en and wg in the embryonic head and brain of Drosophila indicates a refolded band of seven segment remnants Development 1992 116 111-125 
Schmidt-Ott U Gonz&#225;lez-Gait&#225;n M J&#228;ckle H Technau GM Number, identity, and sequence of the Drosophila head segments as revealed by neural elements and their deletion patterns in mutants Proc Natl Acad Sci USA 1994 91 8363-8367 
Scholtz G Evolution of the nauplius stage in malacostracan crustaceans J Zoolog Syst Evol Res 2000 38 175-187 
Scholtz G Edgecombe GD The evolution of arthropod heads: reconciling morphological, developmental and palaeontological evidence Dev Genes Evol 2006 216 395-415 
St Johnston D N&#252;sslein-Volhard C The origin of pattern and polarity in the Drosophila embryo Cell 1992 68 201-219 
Stolt CC Lommes P Sock E Chaboissier MC Schedl A Wegner M The Sox9 transcription factor determines glial fate choice in the developing spinal cord Genes Dev 2003 17 1677-1689 
Tautz D Segmentation Dev Cell 2004 7 301-312 
Thummel CS Pirotta V New pCaSpeR P-element vectors Drosoph Inf Serv 1992 71 150 
Urbach R Technau GM Early steps in building the insect brain: neuroblast formation and segmental patterning in the developing brain of different insect species Arthropod Struct Dev 2003 32 103-123 
Wetering M Oosterwegel M Dooijes D Clevers H Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box EMBO J 1991 10 123-132 
Wetering M Oosterwegel M Norren K Clevers H Sox-4, an Sry-like HMG box protein, is a transcriptional activator in lymphocytes EMBO J 1993 12 3847-3854 
Wetering M Cavallo R Dooijes D Beest M Es J Loureiro J Ypma A Hursh D Jones T Bejsovec A Peifer M Mortin M Clevers H Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF Cell 1997 88 789-799 
Veraksa A McGinnis N Li X Mohler J McGinnis W Cap &#8216;n&#8217; collar B cooperates with a small Maf subunit to specify pharyngeal development and suppress deformed homeotic function in the Drosophila head Development 2000 127 4023-4037 
Vincent A Blankenship JT Wieschaus E Integration of the head and trunk segmentation systems controls cephalic furrow formation in Drosophila Development 1997 124 3747-3754 
Werner MH Huth JR Gronenborn AM Clore GM Molecular basis of human 46X, Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex Cell 1995 81 705-714 
Wilson M Koopman P Matching SOX partner proteins and co-factors of the SOX family of transcriptional regulators Curr Opin Genet Dev 2002 12 441-446 
Wimmer EA Cohen SM J&#228;ckle H Desplan C buttonhead does not contribute to a combinatorial code proposed for Drosophila head development Development 1997 124 1509-1517 
IDF Diabetes Atlas 2009 4th edn Brussels International Diabetes Federation 
IDF Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes 2005 Brussels International Diabetes Federation 
NICE Type 2 Diabetes. The Management of Type 2 Diabetes 2008 London National Institute for Health and Clinical Excellence NICE clinical guideline 66
American Diabetes Association Standards of medical care in diabetes&#8212;2010 Diabetes Care 2010 33 S11-S61 
Gray A Raikou M McGuire A Fenn P Stevens R Cull C Cost-effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). UK Prospective Diabetes Study Group Br Med J 2000 320 1373-1378 
Huang ES Zhang Q Brown SE Drum ML Meltzer DO Chin MH The cost-effectiveness of improving diabetes care in US federally qualified community health centers Health Serv Res 2007 42 2174-2193 
Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 1577-1589 
Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008 358 580-591 
Stratton IM Adler AI Neil HA Matthews DR Manley SE Cull CA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study Br Med J 2000 321 405-412 
UKPDS Research Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 837-853 
Zoungas S de Galan BE Ninomiya T Grobbee D Hamet P Heller S Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial Diabetes Care 2009 32 2068-2074 
American Diabetes Association Diagnosis and classification of diabetes mellitus Diabetes Care 2010 33 S62-S69 
Geistanger A Arends S Berding C Hoshino T Jeppsson JO Little R Statistical methods for monitoring the relationship between the IFCC reference measurement procedure for hemoglobin A1c and the designated comparison methods in the United States, Japan and Sweden Clin Chem 2008 54 1379-1385 
Duke SA Colagiuri S Colagiuri R Individual patient education for people with type 2 diabetes mellitus Cochrane Database Syst Rev 2009 1 CD005268 
Ellis SE Speroff T Dittus RS Brown A Pichert JW Elasy TA Diabetes patient education: a meta-analysis and meta-regression Patient Educ Couns 2004 52 97-105 
Loveman E Frampton GK Clegg AJ The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review Health Technol Assess 2008 12 1-136 
Peyrot M Rubin RR Lauritzen T Snoek FJ Matthews DR Skovlund SE Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study Diabet Med 2005 22 1379-1385 
Simmons D Lillis S Swan J Haar J Discordance in perceptions of barriers to diabetes care between patients and primary care and secondary care Diabetes Care 2007 30 490-495 
Kraushaar LE Kr&#228;mer A Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention BMC Public Health 2009 9 64 
Davies MJ Heller S Skinner TC Campbell MJ Carey ME Cradock S Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial Br Med J 2008 336 491-495 
Stettler C Allemann S J&#252;ni P Cull CA Holman RR Egger M Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials Am Heart J 2006 152 27-38 
Kirkman MS Williams SR Caffrey HH Marrero DG Impact of a program to improve adherence to diabetes guidelines by primary care physicians Diabetes Care 2002 25 1946-1951 
Tabrizi JS O'Rourke PK Wilson AJ Coyne ET Service quality for Type 2 diabetes in Australia: the patient perspective Diabet Med 2008 25 612-617 
Guldberg TL Lauritzen T Kristensen JK Vedsted P The effect of feedback to general practitioners on quality of care for people with type 2 diabetes. A systematic review of the literature BMC Fam Pract 2009 10 30 
Duran A Runkle I Matia P de Miguel MP Garrido S Cervera E Family physician and endocrinologist coordination as the basis for diabetes care in clinical practice BMC Endocr Disord 2008 8 9 
Grant RW Meigs JB Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction Diabetes Care 2007 30 479-484 
The Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu) Diabetes Nutrition and Complications Trial: adherence to the ADA nutritional recommendations, targets of metabolic control, and onset of diabetes complications. A 7-year, prospective, population-based, observational multi-center study J Diabetes Complications 2006 20 361-366 
The Diabetes and Nutrition Study Group of the Spanish Diabetes Association (GSEDNu) Diabetes Nutrition and Complications Trial (DNCT). Diet and risk of microangiopathy progression: the role of polyunsaturated fatty acids and monounsaturated fatty acids consumption Obes Metab 2006 2 6-12 
da Silva R Bach-Faig A Raid&#243; Quintana B Buckland G Vaz de Almeida MD Serra-Majem L Worldwide variation of adherence to the Mediterranean diet, in 1961&#8211;1965 and 2000&#8211;2003 Public Health Nutr 2009 12 1676-1684 
Stacy M Medical treatment of Parkinson disease Neurol Clin 2009 27 3 605-631 
Tanner CM Ross GW Jewell SA Occupation and risk of parkinsonism: a multicenter case-control study Arch Neurol 2009 66 9 1106-1113 
US interim projections by age, sex, race, and hispanic origin: 2000&#8211;2050 Available from:
Cotzias GC Papavasiliou PS Gellene R Modif ication of Parkinsonism &#8211; chronic treatment with L-dopa N Engl J Med 1969 280 7 337-345 
Lang AE Lozano AM Parkinson&#8217;s disease. First of two parts N Engl J Med 1998 339 15 1044-1053 
Nutt JG Motor fluctuations and dyskinesia in Parkinson&#8217;s disease Parkinsonism Relat Disord 2001 8 2 101-108 
Fahn S Oakes D Shoulson I Levodopa and the progression of Parkinson&#8217;s disease N Engl J Med 2004 351 24 2498-2508 
Fahn S The spectrum of levodopa-induced dyskinesias Ann Neurol 2000 47 Suppl 1 2-11 
Golbe LI Young-onset Parkinson&#8217;s disease: a clinical review Neurology 1991 41 2 Pt 1 168-173 
Forno LS Neuropathology of Parkinson&#8217;s disease J Neuropathol Exp Neurol 1996 55 3 259-272 
Jellinger KA Post mortem studies in Parkinson&#8217;s disease &#8211; is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999 56 1-29 
Grace AA Bunney BS The control of firing pattern in nigral dopamine neurons: single spike firing J Neurosci 1984 4 11 2866-2876 
Grace AA Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia Neuroscience 1991 41 1 1-24 
Abercrombie ED Bonatz AE Zigmond MJ Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats Brain Res 1990 525 1 36-44 
Schultz W Predictive reward signal of dopamine neurons J Neurophysiol 1998 80 1 1-27 
Venton BJ Zhang H Garris PA Phillips PE Sulzer D Wightman RM Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing J Neurochem 2003 87 5 1284-1295 
Olanow CW Obeso JA Stocchi F Continuous dopamine-receptor treatment of Parkinson&#8217;s disease: scientific rationale and clinical implications Lancet Neurol 2006 5 8 677-687 
Lewitt PA Levodopa for the treatment of Parkinson&#8217;s disease N Engl J Med 2008 359 23 2468-2476 
Nutt JG Woodward WR Beckner RM Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 1994 44 5 913-919 
Nutt JG Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients Neurology 2000 55 11 Suppl 4 S33-S37 
De la Fuente-Fern&#225;ndez R Sossi V Huang Z Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson&#8217;s disease: implications for dyskinesias Brain 2004 127 Pt 12 2747-2754 
Olanow CW Obeso JA Preventing levodopa-induced dyskinesias Ann Neurol 2000 47 4 Suppl 1 S167-S176 
Nutt JG Carter JH Lea ES Woodward WR Motor fluctuations during continuous levodopa infusions in patients with Parkinson&#8217;s disease Mov Disord 1997 12 3 285-292 
Stocchi F Vacca L Ruggieri S Olanow CW Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study Arch Neurol 2005 62 6 905-910 
Antonini A Isaias IU Canesi M Duodenal levodopa infusion for advanced Parkinson&#8217;s disease: 12-month treatment outcome Mov Disord 2007 22 8 1145-1149 
Pearce RK Banerji T Jenner P Marsden CD De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset Mov Disord 1998 13 2 234-241 
Rascol O Brooks DJ Korczyn AD de Deyn PP Clarke CE Lang AE A five-year study of the incidence of dyskinesia in patients with early Parkinson&#8217;s disease who were treated with ropinirole or levodopa N Engl J Med 2000 342 20 1484-1491 
Olanow CW The scientific basis for the current treatment of Parkinson&#8217;s disease Annu Rev Med 2004 55 41-60 
Stocchi F Rascol O Kieburtz K Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study Ann Neurol 2010 68 1 18-27 
Smith LA Jackson MJ Al-Barghouthy G Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates Mov Disord 2005 20 3 306-314 
Suzuki K Nakazato H Matsui H Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population Cancer 2003 98 7 1411-1416 
Tanaka Y Sasaki M Shiina H Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer Cancer Epidemiol Biomarkers Prev 2006 15 2 238-244 
Shoulson I Glaubiger GA Chase TN On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients Neurology 1975 25 12 1144-1148 
Hardie RJ Lees AJ Stern GM On-off fluctuations in Parkinson&#8217;s disease. A clinical and neuropharmacological study Brain 1984 107 Pt 2 487-506 
Bredberg E Nilsson D Johansson K Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson&#8217;s disease Eur J Clin Pharmacol 1993 45 2 117-122 
Sage JI Schuh L Heikkila RE Duvoisin RC Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson&#8217;s disease Clin Neuropharmacol 1988 11 1 36-44 
Nyholm D Nilsson Remahl AI Dizdar N Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease Neurology 2005 64 2 216-223 
Nilsson D Nyholm D Aquilonius SM Duodenal levodopa infusion in Parkinson&#8217;s disease &#8211; long-term experience Acta Neurol Scand 2001 104 6 343-348 
Devos D Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson&#8217;s disease Mov Disord 2009 24 7 993-1000 
Nyholm D Pharmacokinetics of levodopa/carbidopa infusion with and without oral catechol-O-methyl transferase (COMT) inhibitors (DuoCOMT) Available from:
Pekkonen E Duodenal levodopa infusion, quality of life and autonomic nervous system in Parkinson&#8217;s disease Available from:
Lundqvist C Beiske A Continuous delivery of levodopa in patients with advanced idiopathic Parkinsons disease &#8211; cost-benefit Available from:
Nyholm D Different dyskinesias in Parkinson&#8217;s disease and their relation to levodopa pharmacokinetics (DYSK-PD-2007) Available from:
Kurlan R Rothfield KP Woodward WR Erratic gastric emptying of levodopa may cause &#8220;random&#8221; fluctuations of parkinsonian mobility Neurology 1988 38 3 419-421 
Djaldetti R Baron J Ziv I Melamed E Gastric emptying in Parkinson&#8217;s disease: patients with and without response fluctuations Neurology 1996 46 4 1051-1054 
Pfeiffer RF Gastrointestinal dysfunction in Parkinson&#8217;s disease Lancet Neurol 2003 2 2 107-116 
Goetze O Nikodem AB Wiezcorek J Predictors of gastric emptying in Parkinson&#8217;s disease Neurogastroenterol Motil 2006 18 5 369-375 
Steiger MJ Stocchi F Carta A The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon &#8220;off &#8221; periods in Parkinson&#8217;s disease Clin Neuropharmacol 1991 14 3 241-244 
Stocchi F Fabbri L Vecsei L Krygowska-Wajs A Monici Preti PA Ruggieri SA Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease Clin Neuropharmacol 2007 30 1 18-24 
Stocchi F Zappia M Dall&#8217;Armi V Kulisevsky J Lamberti P Obeso JA Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson&#8217;s disease Mov Disord 2010 25 12 1881-1887 
Chen D An exploratory study of XP21279 (with Lodosyn&#174;) and Sinemet&#174; in Parkinson&#8217;s disease subjects Available from:
Product candidates, XP21279 Available from:
Hsu A Verhagen Metman L Ellenbogen A Comparison of IPX066, a novel extended-release oral carbidopa-levodopa formulation, to immediate-release carbidopa-levodopa in patients with advanced Parkinson&#8217;s disease Am Acad Neurol 2010 74 Suppl 2 A350 
A study to evaluate the safety and efficacy of IPX066 in subjects with Parkinson&#8217;s disease (APEX-PD) Available from:
Ferr&#233; S O&#8217;Connor WT Fuxe K Ungerstedt U The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain J Neurosci 1993 13 12 5402-5406 
Svenningsson P Le Moine C Aubert I Burbaud P Fredholm BB Bloch B Cellular distribution of adenosine A2A receptor mRNA in the primate striatum J Comp Neurol 1998 399 2 229-240 
Ferr&#233; S Fredholm BB Morelli M Popoli P Fuxe K Adenosine&#8211;dopamine receptor&#8211;receptor interactions as an integrative mechanism in the basal ganglia Trends Neurosci 1997 20 10 482-487 
Mori A Shindou T Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists Neurology 2003 61 11 Suppl 6 S44-S48 
Fenu S Pinna A Ongini E Morelli M Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats Eur J Pharmacol 1997 321 2 143-147 
Rose S Ramsay Croft N Jenner P The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats Brain Res 2007 1133 1 110-114 
Kanda T Jackson MJ Smith LA Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann Neurol 1998 43 4 507-513 
Lundblad M Vaudano E Cenci MA Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia J Neurochem 2003 84 6 1398-1410 
Kanda T Jackson MJ Smith LA Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Exp Neurol 2000 162 2 321-327 
Bara-Jimenez W Sherzai A Dimitrova T Adenosine A(2A) receptor antagonist treatment of Parkinson&#8217;s disease Neurology 2003 61 3 293-296 
Hauser RA Hubble JP Truong DD Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD Neurology 2003 61 3 297-303 
Lewitt PA Guttman M Tetrud JW Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces &#8220;off &#8221; time in Parkinson&#8217;s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) Ann Neurol 2008 63 3 295-302 
Stacy M Silver D Mendis T A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease Neurology 2008 70 23 2233-2240 
Hauser RA Shulman LM Trugman JM Study of istradefylline in patients with Parkinson&#8217;s disease on levodopa with motor fluctuations Mov Disord 2008 23 15 2177-2185 
Guttman M Efficacy of istradefylline in Parkinson&#8217;s disease patients treated with levodopa with motor response complications: primary efficacy results of the KW-6002 US-018 study Mov Disord 2006 21 Suppl 15 S585 
KW-6002 to treat Parkinson&#8217;s disease. NCT00006337 Available from:
2nd generation A2A antagonist Available from:
A phase 2, 12-week, double-blind, dose-finding, placebo-controlled study to assess the efficacy and safety of a range of SCH 420814 doses in subjects with moderate to severe Parkinson&#8217;s disease experiencing motor fluctuations and dyskinesias Available from:
Hauser RA Pourcher E Micheli F Efficacy of preladenant, a novel A2A antagonist, as an adjunct to levodopa for the treatment of Parkinson&#8217;s disease Presented at Movement Disorder Society&#8217;s 13th International Congress of Parkinson&#8217;s Disease and Movements Disorders Paris, France 7&#8211;11 Jun 2009 Abstract Tu-185.
Huyck SB Wolski K Cantillon M Impact of A2A receptor antagonist preladenant on dyskinesia in moderate to severe Parkinson&#8217;s disease: post hoc analysis of dose-finding study Presented at Movement Disorder Society&#8217;s 13th International Congress of Parkinson&#8217;s Disease and Movements Disorders Paris, France 7&#8211;11 Jun 2009 Abstract Tu-187. 
A placebo- and active-controlled study of preladenant in early Parkinson&#8216;s disease (study P05664 AM2) Available from: 
A placebo- and active controlled study of preladenant in subjects with moderate to severe Parkinson&#8216;s disease (study P04938 AM2) Available from: 
Synosia Therapeutics Pipeline Available from: 
Sigma-Tau. Research development stages Available from: 
Ross GW Abbott RD Petrovitch H Association of coffee and caffeine intake with the risk of Parkinson disease JAMA 2000 283 20 2674-2679 
Ascherio A Zhang SM Hern&#225;n MA Prospective study of caffeine consumption and risk of Parkinson&#8217;s disease in men and women Ann Neurol 2001 50 1 56-63 
Tan EK Tan C Fook-Chong SM Dose-dependent protective effect of coffee, tea, and smoking in Parkinson&#8217;s disease: a study in ethnic Chinese J Neurol Sci 2003 216 1 163-167 
Hu G Bidel S Jousilahti P Antikainen R Tuomilehto J Coffee and tea consumption and the risk of Parkinson&#8217;s disease Mov Disord 2007 22 15 2242-2248 
Chen JF Xu K Petzer JP Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson&#8217;s disease J Neurosci 2001 21 10 RC143 
Ikeda K Kurokawa M Aoyama S Kuwana Y Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson&#8217;s disease J Neurochem 2002 80 2 262-270 
Pierri M Vaudano E Sager T Englund U KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse Neuropharmacology 2005 48 4 517-524 
Jenner P Mori A Hauser RA Morelli M Fredholm BB Chen JF Adenosine, adenosine A2A antagonists, and Parkinson&#8217;s disease Parkinsonism Relat Disord 2009 15 6 406-413 
Blandini F Armentero MT Fancellu R Blaugrund E Nappi G Neuroprotective effect of rasagiline in a rodent model of Parkinson&#8217;s disease Exp Neurol 2004 187 2 455-459 
Kupsch A Sautter J G&#246;tz ME Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline J Neural Transm 2001 108 8&#8211;9 985-1009 
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 2004 61 4 561-566 
Olanow CW Rascol O Hauser RA A double-blind, delayed-start trial of rasagiline in Parkinson&#8217;s disease N Engl J Med 2009 361 13 1268-1278 
Kieburtz K ADAGIO misses a beat? Lancet Neurol 2009 8 12 1081-1082 
Ahlskog JE Uitti RJ Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010 74 14 1143-1148 
Marzo A Dal Bo L Monti NC Pharmacokinetics and pharmacodynamics of saf inamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity Pharmacol Res 2004 50 1 77-85 
Caccia C Maj R Calabresi M Safinamide: from molecular targets to a new anti-Parkinson drug Neurology 2006 67 7 Suppl 2 S18-S23 
Stocchi F Arnold G Onofrj M Improvement of motor function in early Parkinson disease by safinamide Neurology 2004 63 4 746-748 
Borgohain R Szasz J Bhatt M Efficacy and safety of safinamide in patients with Parkinson&#8217;s disease experiencing motor fluctuations: results of a 6-month phase III, randomized, double-blind, placebo-controlled study 2009 Available from:
Willmer J Safinamide in levodopa induced dyskinesia in Parkinson&#8217;s disease subjects (safinamide-LID) Available from:
Schapira AH Safinamide in the treatment of Parkinson&#8217;s disease Expert Opin Pharmacother 2010 11 13 2261-2268 
Stacy M Galbreath A Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia Clin Neuropharmacol 2008 31 1 51-56 
Hauser RA Rascol O Korczyn AD Ten-year follow-up of Parkinson&#8217;s disease patients randomized to initial therapy with ropinirole or levodopa Mov Disord 2007 22 16 2409-2417 
Holloway R Marek K Biglan K Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease Arch Neurol 2009 66 5 563-570 
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 2002 287 13 1653-1661 
Whone AL Watts RL Stoessl AJ Slower progression of Parkinson&#8217;s disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 2003 54 1 93-101 
Schapira AH Albrecht S Barone P Immediate vs delayed-start pramipexole in early Parkinson&#8217;s disease: the PROUD study Parkinsonism Relat Disord 2009 15 Suppl 2 S81 
Schapira AH Albrecht S Barone P Rationale for delayed-start study of pramipexole in Parkinson&#8217;s disease: the PROUD study Mov Disord 2010 25 11 1627-1632 
Stocchi F Hersh BP Scott BL Nausieda PA Giorgi L Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson&#8217;s disease: a randomized, double-blind, non-inferiority crossover study Curr Med Res Opin 2008 24 10 2883-2895 
Pahwa R Stacy MA Factor SA Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease Neurology 2007 68 14 1108-1115 
Hersh BP Earl NL Hauser RA Stacy M Early treatment benefits of ropinirole prolonged release in Parkinson&#8217;s disease patients with motor fluctuations Mov Disord 2010 25 7 927-931 
Hauser RA Schapira AH Rascol O Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson&#8217;s disease Mov Disord 2010 25 15 2542-2549 
Driver-Dunckley E Samanta J Stacy M Pathological gambling associated with dopamine agonist therapy in Parkinson&#8217;s disease Neurology 2003 61 3 422-423 
Weintraub D Siderowf AD Potenza MN Association of dopamine agonist use with impulse control disorders in Parkinson disease Arch Neurol 2006 63 7 969-973 
Voon V Hassan K Zurowski M Prevalence of repetitive and reward-seeking behaviors in Parkinson disease Neurology 2006 67 7 1254-1257 
Evans AH Strafella AP Weintraub D Stacy M Impulsive and compulsive behaviors in Parkinson&#8217;s disease Mov Disord 2009 24 11 1561-1570 
Weintraub D Koester J Potenza MN Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients Arch Neurol 2010 67 5 589-595 
Thomas A Bonanni L Gambi F di Iorio A Onofrj M Pathological gambling in Parkinson disease is reduced by amantadine Ann Neurol 2010 68 3 400-404 
Weintraub D Sohr M Potenza MN Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study Ann Neurol 2010 68 6 963-968 
Weintraub D Naltrexone for impulse control disorders in Parkinson&#8216;s disease Available from:
Modi G Pillay V Choonara YE Advances in the treatment of neurodegenerative disorders employing nanotechnology Ann N Y Acad Sci 2010 1184 154-172 
Modi G Pillay V Choonara YE Ndesendo VM du Toit LC Naidoo D Nanotechnological applications for the treatment of neurodegenerative disorders Prog Neurobiol 2009 88 4 272-285 
Staples M Microchips and controlled-release drug reservoirs Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010 2 4 400-417 
Linazasoro G Potential applications of nanotechnologies to Parkinson&#8217;s disease therapy Parkinsonism Relat Disord 2008 14 5 383-392 
Bergman H Wichmann T DeLong MR Reversal of experimental parkinsonism by lesions of the subthalamic nucleus Science 1990 249 4975 1436-1438 
Aziz TZ Peggs D Sambrook MA Crossman AR Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate Mov Disord 1991 6 4 288-292 
Benazzouz A Gross C F&#233;ger J Boraud T Bioulac B Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys Eur J Neurosci 1993 5 4 382-389 
Wichmann T Bergman H DeLong MR The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism J Neurophysiol 1994 72 2 521-530 
Kleiner-Fisman G Fisman DN Sime E Saint-Cyr JA Lozano AM Lang AE Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease J Neurosurg 2003 99 3 489-495 
Weaver FM Follett K Stern M Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial JAMA 2009 301 1 63-73 
Follett KA Weaver FM Stern M Pallidal versus subthalamic deep-brain stimulation for Parkinson&#8217;s disease N Engl J Med 2010 362 22 2077-2091 
Mazzone P Lozano A Stanzione P Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson&#8217;s disease Neuroreport 2005 16 17 1877-1881 
Plaha P Gill SS Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson&#8217;s disease Neuroreport 2005 16 17 1883-1887 
Moro E Hamani C Poon YY Unilateral pedunculopontine stimulation improves falls in Parkinson&#8217;s disease Brain 2010 133 Pt 1 215-224 
Ferraye MU Deb&#251; B Fraix V Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson&#8216;s disease Brain 2010 133 Pt 1 205-214 
Benabid AL Chabardes S Mitrofanis J Pollak P Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson&#8217;s disease Lancet Neurol 2009 8 1 67-81 
Benabid AL Pollak P Gao D Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders J Neurosurg 1996 84 2 203-214 
Meissner W Leblois A Hansel D Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations Brain 2005 128 Pt 10 2372-2382 
Welter ML Houeto JL Bonnet AM Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients Arch Neurol 2004 61 1 89-96 
Xia R Berger F Piallat B Benabid AL Alteration of hormone and neurotransmitter production in cultured cells by high and low frequency electrical stimulation Acta Neurochir (Wien) 2007 149 1 67-73 
Harnack D Meissner W Jira JA Winter C Morgenstern R Kupsch A Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive Parkinsonism Exp Neurol 2008 210 1 257-260 
Maesawa S Kaneoke Y Kajita Y Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons J Neurosurg 2004 100 4 679-687 
Temel Y Visser-Vandewalle V Kaplan S Protection of nigral cell death by bilateral subthalamic nucleus stimulation Brain Res 2006 1120 1 100-105 
Wallace BA Ashkan K Heise CE Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys Brain 2007 130 Pt 8 2129-2145 
Spieles-Engemann AL Behbehani MM Collier TJ Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss Neurobiol Dis 2010 39 1 105-115 
Bergman H Wichmann T Karmon B DeLong MR The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism J Neurophysiol 1994 72 2 507-520 
Crossman AR Mitchell IJ Sambrook MA Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey Neuropharmacology 1985 24 6 587-591 
Eidelberg D Moeller JR Dhawan V The metabolic topography of parkinsonism J Cereb Blood Flow Metab 1994 14 5 783-801 
Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson&#8217;s disease N Engl J Med 2001 345 13 956-963 
Charles PD van Blercom N Krack P Predictors of effective bilateral subthalamic nucleus stimulation for PD Neurology 2002 59 6 932-934 
Deuschl G Schade-Brittinger C Krack P A randomized trial of deep-brain stimulation for Parkinson&#8217;s disease N Engl J Med 2006 355 9 896-908 
Volkmann J Deep brain stimulation for the treatment of Parkinson&#8217;s disease J Clin Neurophysiol 2004 21 1 6-17 
Morgante L Morgante F Moro E How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire Parkinsonism Relat Disord 2007 13 8 528-531 
Espay AJ Vaughan JE Marras C Fowler R Eckman MH Early versus delayed bilateral subthalamic deep brain stimulation for parkinson&#8217;s disease: a decision analysis Mov Disord 2010 25 10 1456-1463 
Deuschl G Controlled trial of deep brain stimulation in early patients with Parkinson&#8217;s disease Available from:
Charles PD Deep brain stimulation (DBS) for early stage Parkinson&#8217;s disease (PD) Available from:
Keeler CE Gene therapy J Hered 1947 38 10 294-298 
Morrow JF The prospects for gene therapy in humans Ann N Y Acad Sci 1976 265 13-21 
Nagatsu T Sawada M Biochemistry of postmortem brains in Parkinson&#8217;s disease: historical overview and future prospects J Neural Transm Suppl 2007 72 113-120 
Bankiewicz KS Forsayeth J Eberling JL Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC Mol Ther 2006 14 4 564-570 
Shen Y Muramatsu S Ikeguchi K Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson&#8217;s disease Hum Gene Ther 2000 11 11 1509-1519 
Muramatsu S Fujimoto K Ikeguchi K Behavioral recovery in a primate model of Parkinson&#8217;s disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes Hum Gene Ther 2002 13 3 345-354 
Jarraya B Boulet S Ralph GS Dopamine gene therapy for Parkinson&#8217;s disease in a nonhuman primate without associated dyskinesia Sci Transl Med 2009 1 2 2ra4 
Oxford BioMedica announces two-year phase I/II results of ProSavin&#174; in Parkinson&#8217;s disease &#8211; 6/14/2010 Available from:
Palfi S Phase I/II study of the safety, efficacy and dose evaluation of ProSavin for the treatment of bilateral idiopathic Parkinson&#8217;s disease Available from:
Bankiewicz KS Eberling JL Kohutnicka M Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach Exp Neurol 2000 164 1 2-14 
Eberling JL Jagust WJ Christine CW Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 2008 70 21 1980-1983 
Muramatsu S Fujimoto K Kato S A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson&#8217;s disease Mol Ther 2010 18 9 1731-1735 
Stocchi F Ruggieri S Vacca L Olanow CW Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson&#8217;s disease Brain 2002 125 Pt 9 2058-2066 
Nutt JG Obeso JA Stocchi F Continuous dopamine-receptor stimulation in advanced Parkinson&#8217;s disease Trends Neurosci 2000 23 10 Suppl S109-S115 
Chase TN Levodopa therapy: consequences of the nonphysiologic replacement of dopamine Neurology 1998 50 5 Suppl 5 S17-S25 
Carlsson T Winkler C Burger C Reversal of dyskinesias in an animal model of Parkinson&#8217;s disease by continuous L-DOPA delivery using rAAV vectors Brain 2005 128 Pt 3 559-569 
Kaplitt MG Feigin A Tang C Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson&#8217;s disease: an open label, phase I trial Lancet 2007 369 9579 2097-2105 
Stoessl AJ Gene therapy for Parkinson&#8217;s disease: early data Lancet 2007 369 9579 2056-2058 
Schapira AH Olanow CW Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 2004 291 3 358-364 
Lin LF Doherty DH Lile JD Bektesh S Collins F GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 1993 260 5111 1130-1132 
Nutt JG Burchiel KJ Comella CL Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 2003 60 1 69-73 
Kordower JH Palfi S Chen EY Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson&#8217;s disease Ann Neurol 1999 46 3 419-424 
Kirik D Rosenblad C Bjorklund A Mandel RJ Long-term rAA V-mediated gene transfer of GDNF in the rat Parkinson&#8217;s model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system J Neurosci 2000 20 12 4686-4700 
Wang L Muramatsu S Lu Y Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson&#8217;s disease Gene Ther 2002 9 6 381-389 
Kordower JH Emborg ME Bloch J Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson&#8217;s disease Science 2000 290 5492 767-773 
Lo Bianco C D&#233;glon N Pralong W Aebischer P Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson&#8217;s disease Neurobiol Dis 2004 17 2 283-289 
Gill SS Patel NK Hotton GR Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat Med 2003 9 5 589-595 
Patel NK Bunnage M Plaha P Svendsen CN Heywood P Gill SS Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study Ann Neurol 2005 57 2 298-302 
Lang AE Gill S Patel NK Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [Erratum in: Ann Neurol. 2006;60(6):747] Ann Neurol 2006 59 3 459-466 
Gasmi M Herzog CD Brandon EP Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson&#8217;s disease Mol Ther 2007 15 1 62-68 
Gasmi M Brandon EP Herzog CD AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson&#8217;s disease Neurobiol Dis 2007 27 1 67-76 
Kordower JH Herzog CD Dass B Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys Ann Neurol 2006 60 6 706-715 
Marks WJ Jr Ostrem JL Verhagen L Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson&#8217;s disease: an open-label, phase I trial Lancet Neurol 2008 7 5 400-408 
Siffert J Double-blind, multicenter, sham surgery controlled study of CERE-120 in subjects with idiopathic Parkinson&#8217;s disease Available from:
Klejbor I Stachowiak EK Bharali DJ ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology J Neurosci Methods 2007 165 2 230-243 
Parkinson J An Essay on the Shaking Palsy London Sherwood, Neely and Jones 1817 
